Pair page
DS5 with Semax
Mechanism-tag overlap and published literature for DS5 and Semax, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
blenddihexa-semax-nootropic-stack
acth-analogneuroprotectivenootropic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying DS5 and Semax have published these mechanism-level observations. Not a co-administration recommendation.
The BDNF / melanocortin leg of DS5. 30 years of Russian clinical experience, approved in Russia as Semax 0.1% nasal spray for cerebral circulatory disorders and Semax 1% for ischemic stroke. More robust individual evidence base than dihexa.
Quick facts
DS5
Semax
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | DS5 | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2018 | DS5 | Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. | human study |
| 2021 | DS5 | Sun X, Deng Y, Liang J, Lin Y, Song J, Zhao S, Zhuang G, Jia Z. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Oct 28;11(11):1421. PMID: 34827487. PMID 34827487 | preclinical, in vivo |
| 2006 | DS5 | Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of adrenocorticotropin (4-10), activates expression of BDNF in rat basal… | preclinical, in vivo |
| 2026 | DS5 | WADA Prohibited List 2026. World Anti-Doping Agency. | regulatory / registry |
| 2025 | DS5 | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
| 2015 | DS5 | Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. PMID: 25674052. PMID 25674052 | research article |
| 2014 | DS5 | Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402. PMID: 25187433. RETRACTED April 2025. PMID 25187433 | research article |
| 2013 | DS5 | McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013 Jan;344(1):141-54. PMID: 23055539. (Foundational… PMID 23055539 | research article |
| 2002 | Semax | Skvortsova VI, Platonova IA, Tvorogova TV, Miasoedov NF. Effect of semax on disability and handicap indexes in patients survived carotid ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(Suppl 5):36-39. | human study |
| 2020 | Semax | Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681. | preclinical, in vivo |
| 2013 | Semax | Glazova NY, Sebentsova EA, Manchenko DM, et al. Prolonged beneficial effect of neonatal treatment with Semax on the grooming behavior of elderly rats. Bull Exp Biol Med. 2013;155(6):731-733. | preclinical, in vivo |
| 2011 | Semax | Stavchansky VV, Tvorogova TV, Botsina AY, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on expression of neurotrophins and their receptors in rat brain during incomplete global ischemia. Mol Biol (Mosk). 2011;45(6):1026-10… | preclinical, in vivo |
| 2010 | Semax | Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. | preclinical, in vivo |
| 2007 | Semax | Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, Myasoedov NF. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neurosci Lett. 2007;417(2):201-205. | preclinical, in vivo |
| 2007 | Semax | Storozheva ZI, Proshin AT, Sherstnev VV, Stolyarov ID, Boĭko AN. Effects of Semax on different forms of learning and memory in adult and aged rats. Bull Exp Biol Med. 2007;143(4):482-485. | preclinical, in vivo |
| 2006 | Semax | Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID: 16635254. PMID 16635254 | preclinical, in vivo |
| 2006 | Semax | Volkova MV, Shadrina MI, Kolomin TA, Dolotov OV, Grivennikov IA, Shaburova EV, Solntseva OS, Myasoedov NF, Limborska SA, Slominsky PA. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.… PMID 16996037 | preclinical, in vivo |
| 1991 | Semax | Potaman VN, Antonova LV, Dubynin VA, et al. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;130(1):11-13. | preclinical, in vivo |
| 2001 | Semax | Kost NV, Sokolov OY, Gabaeva MV, Grivennikov IA, Andreeva LA, Myasoedov NF, Zozulya AA. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorg Khim. 2001;27(3):180-183. PMID: 11443939. PMID 11443939 | research article |
| 1997 | Semax | Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EIu, Vanichkin AV. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472. PMID 11517472 | research article |
Related pair pages
More research context
Frequently asked
Have DS5 and Semax been studied together?
Researchers have published mechanistic-level co-administration discussion of DS5 and Semax. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do DS5 and Semax share?
DS5 and Semax do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of DS5 and Semax?
DS5: Research only. Semax: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on DS5 and Semax?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the DS5 profile and the Semax profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026